Senate Panel Backs Penalizing Drugmakers for their 340B Contract Pharmacy Actions

The Democratic-controlled Senate Appropriations Committee says it's pleased with HRSA's response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

U.S. Senate appropriators say they’re happy with the federal government’s response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

Please Login or Become a Paid Subscriber to View this Content

Read More »

340B Report Publisher and CEO: If Congress Flips Next Year, Expect 340B To Get A Very Close Look

Ted Slafsky
If Congress changes hands during next year’s mid-term elections, expect a renewed effort to place significant restrictions on the 340B program, 340B Report Publisher and CEO Ted Slafsky predicts.

If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes

Read More »

Kalderos Sues HHS and HRSA, Says Ban on Drug Company Conditions on 340B Sales is Illegal

A mock-up of Request, one of the modules that make up Kalderos' 340B Pay service to enable drug manufacturers to provide 340B ceiling prices as rebates instead of as discounts.

Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.

Please Login or Become

Read More »

Montana GOP Congressman Proposes a Host of New Conditions on 340B Hospitals

First-term U.S. Rep. Matt Rosendale (R-Mont.) has introduced a bill to impose a host of new conditions on hospital participation in the 340B drug discount program.

Montana’s at-large Republican U.S. congressman has introduced a bill to impose a host of new conditions on hospital participation in the drug discount program.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Half of Congressional Black Caucus Asks CMS to End Medicare Drug Payment Cuts for 340B Hospitals

Reps. Robin Kelly (D-Ill.), left, and Lisa Blunt Rochester (D-Del.), right, led the Sept. 24 letter urging CMS to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

Please Login

Read More »

Rough Sailing for Drug Pricing Reform in Congress

Congressional Democrats continue to wrangle over a $3.5 trillion economic and social welfare bill that is expected to include major drug pricing reforms.

It appears increasingly likely that congressional Democrats will miss their self-appointed deadline to pass and sent to President Biden this week a $3.5 trillion economic and social welfare bill including major drug pricing reforms.

Please Login

Read More »

GOP Senator Files Bill to Preserve Trump’s 340B Insulin/EpiPen Mandate

Sen. John Kennedy (R-La.) has introduced legislation to preserve the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income, uninsured, and/or underinsured patients.

A Republican U.S. senator on an important health care spending committee wants Congress to pass a law preserving the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income,

Read More »

Hospitals Ask Hill Leaders to Shield 340B, as Vote Nears on Drug Pricing Reform

Hospital groups urged congressional leaders in a Sept. 24 letter to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.

Six national hospital groups late last week urged Democratic and Republican congressional leaders to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.

Please Login or

Read More »

Seven-Term Senator Grassley, Often Attuned to 340B, Will Run Again in 2022

Sen. Chuck Grassley (R-Iowa), one of the most-engaged members of Congress on 340B matters, is seeking an eighth Senate term.

U.S. Sen. Chuck Grassley (R-Iowa)—one of the most-engaged members of Congress on 340B matters—has announced he will seek an eighth Senate term in next year’s congressional elections.

Please Login or Become a Paid Subscriber to View

Read More »

News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income

Senator Mike Braun (R-IN) has introduced legislation to let the government audit 340B entities to determine how they use net income from 340B savings.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.

Please Login or Become

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report